Feb 07, 2025 8:00am EST Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Jan 30, 2025 5:17pm EST Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Jan 27, 2025 8:30pm EST Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Oct 30, 2024 4:15pm EDT Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
Oct 02, 2024 4:05pm EDT Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Sep 03, 2024 8:00am EDT Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Jul 30, 2024 8:00am EDT Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Jul 17, 2024 8:00am EDT Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
